Steven M. Greenberg, MD, PhD, FAHA, Chair; Wendy C. Ziai, MD, MPH, FAHA, Vice Chair;
Charlotte Cordonnier, MD, PhD; Dar Dowlatshahi, MD, PhD, FAHA; Brandon Francis, MD …

Importance Direct oral anticoagulant (DOAC)–associated intracranial hemorrhage (ICH) has
high morbidity and mortality. The safety and outcome data of DOAC reversal agents in ICH …

This guidance document was prepared on behalf of the International Council for
Standardization in Haematology (ICSH) for providing haemostasis-related guidance …

Abstract Background Direct oral anticoagulants (DOACs) have shown a positive benefit-risk
balance in both clinical trials and real-world data, but approximately 2% to 3.5% of patients …

Background Andexanet alfa is approved (FDA “accelerated approval”; EMA “conditional
approval”) as the first specific reversal agent for factor Xa (FXa) inhibitor-associated …

Abstract Background/Objective There are limited data on the risks and benefits of using
andexanet alfa (AA) in comparison with four-factor prothrombin complex concentrate (4F …

In 2018, the International Council for Standardization in Haematology (ICSH) published a
consensus document providing guidance for laboratories on measuring direct oral …

Background and Purpose: It is unestablished whether andexanet alfa, compared with
guideline-based usual care including prothrombin complex concentrates, is associated with …

In urgent clinical situations, such as trauma, urgent surgery or before thrombolysis, rapid
quantification of direct oral anticoagulant plasma drug levels is warranted. Using the …

OBJECTIVES: To combine evidence on andexanet alfa and prothrombin complex
concentrates for factor Xa inhibitor-associated bleeding to guide clinicians on reversal …